TABLE 37Comparison of the results of the PenTAG AR,2 BMS3 and Novartis4 models compared with the base treatment (discounted)

AnalysisBase treatmentInterventions
HU-SCTIFNNilotinibHDIDasatinib
Total cost (£)PenTAG298,900161,300172,400221,300
BMS3129,292318,978350,365314,413
Novartis480,933139,216146,234
Total QALYPenTAG26.2297.637.3117.846
BMS31.6646.2355.916.425
Novartis43.184.514.28
Incremental cost vs base treatment (£)PenTAG262,40073,500122,400
BMS3189,686221,073185,121
Novartis458,28365,301
Incremental QALY vs base treatmentPenTAG21.4011.0821.617
BMS34.5714.2464.761
Novartis41.331.10
ICER vs base treatment (£ per QALY)PenTAG244,54067,93075,696
BMS341,49852,06638,883
Novartis443,82259,364

HDI, high-dose imatinib; HU, hydroxycarbamide; IFN, interferon; SCT, stem cell transplantation.

From: 4, Economic analysis

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.